Vitro Diagnostics, Inc. , dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer.
Cancer stem cells are thought to generate cancerous tumors, and while some of these tumor cells |
Vitro’s proprietary stem cell technology and products, now subject to pending patent protection, may lead to novel cell therapy for cancer.
The Company is pursuing suitable strategic partners to commercialize these novel therapeutic products. Furthermore, the Company has also commercialized various modified stem cell lines and related products to support cancer stem cell research including the development of new methods to target the selective eradication of cancer stem cells, which is essential to therapeutic efficacy. These products and other tools for use in stem cell research are now commercially available ( www.vitrobiopharma.com/ : ).
Dr. Rice, a member of Vitro’s SAB and a University of Colorado cancer researcher said, “Cellular-mediated destruction of cancer stem cells represents a promising new avenue for the development of effective treatments that specifically target cancer stem cells. Vitro has developed an exciting portfolio of products to advance research in this field, which is one of the few approaches to show promise against intractable cancers such as most forms of brain cancer. Additionally, Vitro’s patent pending technology for cancer therapy represents an exciting and novel approach to the selective eradication of cancer stem cells that could usher in new promise in the fight against cancer.”
0 comments:
Post a Comment